CN1058965A - 制备新的喹啉衍生物的方法 - Google Patents

制备新的喹啉衍生物的方法 Download PDF

Info

Publication number
CN1058965A
CN1058965A CN91105053A CN91105053A CN1058965A CN 1058965 A CN1058965 A CN 1058965A CN 91105053 A CN91105053 A CN 91105053A CN 91105053 A CN91105053 A CN 91105053A CN 1058965 A CN1058965 A CN 1058965A
Authority
CN
China
Prior art keywords
group
alkyl
ethyl
formula
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN91105053A
Other languages
English (en)
Chinese (zh)
Inventor
A·H·拉特克利夫
E·G·威廉斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imperial Chemical Industries Ltd
Original Assignee
Imperial Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Chemical Industries Ltd filed Critical Imperial Chemical Industries Ltd
Publication of CN1058965A publication Critical patent/CN1058965A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN91105053A 1990-08-09 1991-07-24 制备新的喹啉衍生物的方法 Pending CN1058965A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9017479.8 1990-08-09
GB909017479A GB9017479D0 (en) 1990-08-09 1990-08-09 Process

Publications (1)

Publication Number Publication Date
CN1058965A true CN1058965A (zh) 1992-02-26

Family

ID=10680406

Family Applications (1)

Application Number Title Priority Date Filing Date
CN91105053A Pending CN1058965A (zh) 1990-08-09 1991-07-24 制备新的喹啉衍生物的方法

Country Status (15)

Country Link
EP (1) EP0495948A1 (cs)
JP (1) JPH05501728A (cs)
KR (1) KR920702357A (cs)
CN (1) CN1058965A (cs)
AU (1) AU8309091A (cs)
CA (1) CA2047249A1 (cs)
CS (1) CS88692A3 (cs)
FI (1) FI921319A0 (cs)
GB (2) GB9017479D0 (cs)
HU (1) HUT60490A (cs)
IE (1) IE912406A1 (cs)
IL (1) IL98833A0 (cs)
PT (1) PT98607A (cs)
WO (1) WO1992002508A1 (cs)
ZA (1) ZA915567B (cs)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5246944A (en) * 1991-08-13 1993-09-21 Merck & Co., Inc. Quinoline angiotensin ii antagonists incorporating a substituted benzyl element
US5484955A (en) * 1992-07-06 1996-01-16 Takeda Chemical Industries, Ltd. Tri-higher alkyl tin azide and its use
US6608048B2 (en) 2000-03-28 2003-08-19 Wyeth Holdings Tricyclic protein kinase inhibitors
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
RS60093B1 (sr) 2013-09-16 2020-05-29 Astrazeneca Ab Terapeutske polimerne nanočestice i postupci njihove pripreme i primene

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820843A (en) * 1987-05-22 1989-04-11 E. I. Du Pont De Nemours And Company Tetrazole intermediates to antihypertensive compounds
US4920132A (en) * 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
EP0412848B1 (en) * 1989-08-11 1995-01-18 Zeneca Limited Quinoline derivatives, process for their preparation and their use as medicaments

Also Published As

Publication number Publication date
AU8309091A (en) 1992-03-02
PT98607A (pt) 1992-06-30
IL98833A0 (en) 1992-07-15
JPH05501728A (ja) 1993-04-02
CS88692A3 (en) 1992-10-14
FI921319L (fi) 1992-03-26
GB9017479D0 (en) 1990-09-26
EP0495948A1 (en) 1992-07-29
FI921319A7 (fi) 1992-03-26
HU9200933D0 (en) 1992-05-28
GB9115250D0 (en) 1991-08-28
WO1992002508A1 (en) 1992-02-20
IE912406A1 (en) 1992-02-12
CA2047249A1 (en) 1992-02-10
KR920702357A (ko) 1992-09-03
HUT60490A (en) 1992-09-28
FI921319A0 (fi) 1992-03-26
ZA915567B (en) 1992-07-29

Similar Documents

Publication Publication Date Title
RU2026285C1 (ru) Способ получения бифенилкарбонитрилов
US5444071A (en) Quinoline derivatives and use thereof as angiotensin II antagonists
FI93957B (fi) Menetelmä pyrimidiinien valmistamiseksi
CN1058965A (zh) 制备新的喹啉衍生物的方法
EP0470794A1 (en) Process for the preparation of nitriles
JP2010535743A (ja) オルメサルタンメドキソミルの調製のための方法
JPH05148197A (ja) フエノキシフエニル誘導体
WO2006135641A2 (en) PROCESS FOR THE SYNTHESIS OF 5- (METHYL-lH-IMIDAZOL-l-YL) -3- (TRI FLUOROME TH YL) -BENZENEAMINE
JPH06199838A (ja) 三置換ビフエニル
JPH11509237A (ja) ピリミジン誘導体の製造方法
CN1064809A (zh) 药剂
US4156002A (en) Pharmaceutical compositions
KR20080103608A (ko) 디벤조[ｂ,ｆ]아제핀 중간체
JP2005520809A (ja) 固体のベンズアゼピン化合物の塩および医薬化合物の調製におけるそれらの使用
US5977372A (en) Chloro or bromo[2-[2-(tert-butyl)-2H-tetrazol-5-yl]phenyl]zinc intermediates
CN1033273A (zh) 3-取代-4-(苯基阿尼洛)哌啶化合物和衍生物的立体有择制备
JP3957795B2 (ja) フラボン誘導体及びこれを含有する医薬
US4820723A (en) Disubstituted tetrazole leukotriene antagonists and methods for their use thereas
JP5118963B2 (ja) カルベジロールの製造方法
JPH0517214B2 (cs)
EP0288190A1 (en) Improvements in or relating to leukotriene antagonists
CN1143843C (zh) 三氟甲基磺酸2－三甲基铵－4，5－二甲氧基苯甲醛的制备方法
CA2137049A1 (en) Amino acid salts of and methods for preparing antihypercholesterolemic tetrazole compounds
EP1891053A1 (en) Method for obtaining benzimidazole derivatives and intermediates thereof
JP2941178B2 (ja) アミノベンゾエイト化合物の製造法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication